Madrigal Pharmaceuticals (MDGL) said Wednesday that patients with metabolic dysfunction-associated steatohepatitis treated with its Rezdiffra drug showed "marked reductions" in liver stiffness.

After two years of treatment with the drug, the vibration-controlled transient elastography results of 101 patients showed a statistically significant reduction in liver stiffness, the company said.

The late-stage trial of Rezdiffra included an open-label active treatment arm for patients with compensated MASH cirrhosis.

The company said 51% of the patients achieved a 25% or greater reduction in liver stiffness, which has been linked to a reduced progression to end-stage liver disease.

Madrigal said it plans to present additional trial results from the compensated MASH cirrhosis arm at a future medical conference.